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Disseminated intravascular coagulation (DIC) with excessive fibrinolysis (XFL) is a rare and acute life-threatening variant of DIC
in patients with prostate cancer. Patients present with coagulopathy, hypofibrinogenemia, and systemic bleeding. We describe a
case of DIC XFL caused by prostate cancer (PC) successfully treated with a single injection of degarelix, a gonadotropin-releasing
hormone (GnRH) receptor antagonist. This led to prompt control of the patient’s coagulopathy within ten days of treatment.
Our case highlights features of this rare and devastating hemorrhagic complication of PC along with a fast-acting and effective
therapeutic drug option.
1. Case Description
A 61-year-old Hispanic man with past medical history of
benign prostatic hyperplasia (BPH) treated with transure-
thral resection of the prostate the preceding year presented
to our emergency room with a nonhealing wound on his
right thigh. He reported that he sustained a laceration to his
right thigh during work with machinery one week prior to
presentation and had visited the nearest urgent care. Despite
suture placement at the urgent care, he continued to bleed.
In addition, he reported multiple ecchymoses on his lower
abdomen and extremities and severe pain in his left hip and
leg.The patient had a temperature of 36.5∘C, a heart rate of 101
beats per minute, a blood pressure of 138/87mmHg, a respi-
ratory rate of 18 breaths perminute, and an oxygen saturation
of 98% on room air. Physical exam revealed skin pallor along
with diffuse ecchymoses of the abdomen, thighs, and extrem-
ities. No lymphadenopathy was noted. Labs revealed a WBC
of 7.9 (normal 3.4–10.4 1000/𝜇L), hemoglobin 8.2 (normal
13.5–17.5 g/dL), hematocrit 24.8 (normal 40.0–51.0%), platelet
counts of 76 (normal 150–425 1000/𝜇L), INR 1.8 (normal 0.8–
1.1), PT 20.9 (normal 11.9–15.0 seconds), PTT 46.9 (normal
22.6–35.5 seconds), fibrinogen 40 (normal 200–430mg/dL),
alkaline phosphatase 1193 (normal 40–150 IU/L), and D-
dimer>20.0 (normal<0.5 𝜇g/mL).The patient was started on
4 units of fresh frozen plasma and 1 unit of cryoprecipitate,
and a DIC panel was obtained every 6 hours.
AnX-ray of the lefthip and femur demonstrated extensive
metastatic lesions of the left ilium, ischium, and pubic bones
including involvement of the acetabulum. A contrast-
enhanced chest CT revealed focal periosteal reaction in the
left posteromedial 6th, 7th, and 8th ribs along with nonho-
mogenous mixed sclerotic and lytic appearance in the spine.
An abdominal MRI with and without contrast demonstrated
diffuse osseousmetastatic disease but no evidence of primary
malignancy in the abdomen. Nuclear medicine whole body
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Figure 1: Sagittal contrast-enhanced T1-weighted image of the thoracic spine (a) demonstrates multiple deposits of enhancing soft tissue in
the ventral aspect of the epidural space (arrows) consistent with epidural metastatic disease in this patient with prostate cancer. Also note
the heterogeneous bone marrow signal consistent with diffuse osseous metastatic disease. A follow-up study obtained just 39 days later (b)
demonstrates resolution of epidural metastasis (arrows). Sagittal reconstruction from a thoracic spine CT (c) demonstrates patchy sclerosis
in the bone consistent with diffuse osseous metastatic disease.
bone scan revealed diffuse osseous metastatic disease involv-
ing the axial and proximal appendicular skeleton along with
bilateral involvement of the femurs. Spinal MRI with and
without contrast demonstrated diffuse osseous metastatic
disease involving the cervical, thoracic, lumbar spine, and
sacrum. The MRI also demonstrated an unusual finding of
extensive metastatic epidural tumor deposits along the tho-
racic and lumbosacral spine resulting in spinal canal stenosis
(Figure 1). The patient required transfusions of cryoprecipi-
tate (CP), fresh frozen plasma (FFP), platelets (PLTs), and red
blood cells (PRBCs) pending workup (Figures 2(a) and 2(b)).
Prostate serum antigen (PSA) and𝛼2-antiplasmin (AAP) lev-
els were ordered and revealed PSA and AAP levels of 673.17
(normal 0.0–4.0 ng/mL) and 42 (normal 88–120%), respec-
tively. The significantly decreased fibrinogen and AAP levels
in conjunction with high PSA indicated PC with DIC XFL as
the diagnosis. A prostate biopsy was not attempted given the
high risk of bleeding. The patient received two subcutaneous
injections of degarelix 120mg on each side of his abdomen
(total 240mg), followed immediately by cold compresses to
both areas to prevent bleeding. Over the next 7 days, he was
transfused with CP, PRBCs, PLTs, and FFP. He also received
Vitamin K 5mg daily. Coagulopathy marker goals were fib-
rinogen level > 100mg/dL, hemoglobin > 8 g/dL, and platelet
count > 50,000/𝜇L. Ten days after admission, his coagulop-
athy improved obviating the need for transfusions (Figures
2(a) and 1(b)).
The patient was observed an additional two days and did
not require supportive transfusions and was discharged on
day 13 after admission. Over the course of his encounter, he
received a total of 70 units of CP, 8 units of FFP, 4 units of
PRBCs, and 3 units of PLTs. His lab values upon discharge
were platelets 139,000/𝜇L, INR 1.1, PT 14.4 sec, PTT 22.4 sec,
fibrinogen 141mg/dL, alkaline phosphatase 600 IU/L, and
PSA 125.70 ng/mL.
During an outpatient followup, the patient was stable and
his labs revealed no coagulopathy and his D-dimer remained
persistently elevated. He decided against pursuing a prostate
biopsy given his concerns of bleeding and low likelihood
that results will change management. MRI of the spine one
month after starting testicular suppression revealed complete
resolution of the epidural deposits (Figure 1). After 3 months
of treatment with degarelix his PSA decreased to 26 and he
achieved a very good partial response by imaging. Sixmonths
after starting hormonal therapy he developed urinary reten-
tion requiring hospitalization and urinary catheter place-
ment. His PSA increased to 555 and a bone scan and an MRI
of the spine, abdomen, and pelvis revealed extensive bone
metastasis in thoracic and lumbar spine, femur, ribs, and pel-
vis. Bicalutamide was added; however, his disease progressed
with a PSA level of 1361 and an alkaline phosphatase level
of 1247 (normal 40–150 IU/L). He was started on docetaxel
and received 3 cycles of therapy. His PSA remained elevated
at 1200 and his performance status worsened significantly
(Karnofsky performance status of 60%) necessitating admis-
sion to a rehab center. The patient shortly after decided on
comfort care.
2. Discussion
PC is the most frequently diagnosed nonskin malignancy in
men and the third leading cause of cancer deaths in the USA
[1]. Patients can present with various disease manifestations
but localized lower urinary tract symptoms that include
urinary retention, frequency, hesitancy, nocturia, and hema-
turia are the most common complaints [2]. Hematological
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T1: first transfusion (cryoprecipitate, platelets, FFP, and RBC)
T2: second transfusion (cryoprecipitate, platelets, FFP, and RBC)
T3: third transfusion (cryoprecipitate, platelets, and RBC)
D: degarelix 240mg subcutaneous injection
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T1: first transfusion (cryoprecipitate, platelets, FFP, and RBC)
T2: second transfusion (cryoprecipitate, platelets, FFP, and RBC)
T3: third transfusion (cryoprecipitate, platelets, and RBC)




Figure 2: Graph (a) demonstrates the time of administration of degarelix and fibrinogen, platelets, and INR trends over the course of
hospitalization. (b) Graph demonstrates PT and PTT trends over the course of hospitalization.
disorders associated with PC include thrombotic thrombocy-
topenia, primary fibrinolysis, sterile thrombotic endocarditis,
and thrombosis [3]. DIC, however, is the most common
hematological ailment observed in PC patients (13–30%)
[3, 4]. The exact pathophysiology underlying the association
between PC and DIC is partially understood [5]. Previ-
ous reports indicated that tumor cells express a variety of
procoagulant molecules, including tissue factor (TF), which
activates the host’s hemostatic system leading to thrombosis
and consumption of the coagulation factors culminating to
DIC [6]. Recent data further elucidated this hypothesis by
identifying the release of microparticles (MP) from tumor
cells (membrane blebs that are released from the cell surface)
as the main culprit stimulating the coagulation cascade [7].
MP provide a membrane surface for the assembly of the
components of the coagulation protease cascade. In addition,
the presence of anionic phospholipids (phosphatidylserine)
and TF in MP increases the procoagulant activity through
activation of factor VII and the extrinsic coagulation cascade
leading to DIC [7]. Patients present with elevated PT, PTT,
INR, D-dimer, fibrin or fibrinogen degradation products,
thrombin-antithrombin complex, positive fibrin monomer
test, low PLTs, and normal or near normal fibrinogen levels
(indicating that fibrinolysis is compensated) [5, 8]. Patients
with PC and DIC with underlying compensated fibrinolysis
rarely present with bleeding (0.4 to 1.65%) and tend to
develop thrombotic rather than hemorrhagic complications
[5, 8]. Conversely, patients with PC and XFL usually develop
a unique and life-threatening form of DICmanifested by sys-
temic intracavitary, intracutaneous, and intracranial bleeding
[5]. This is secondary to hypofibrinogenemia due to uncom-
pensated XFL that might result from the overproduction
of urinary-type plasminogen activators (uPA) by prostate
cancer cells or the depletion of fibrinolytic inhibitors such as
AAP [9, 10]. Plasmin activity is regulated by the enzymeAAP,
which inactivates plasmin and limits its actions. When the
level of AAP falls below 60% of normal then plasmin is able
to degrade fibrinogen, thus resulting in XFL and a bleeding
diathesis [10]. PC cells produce an excess amount of uPA that
increase the amount of circulating plasmin [11].
In the largest retrospective study of PCwithDIC andXFL
(defined as hypofibrinogenemia, coagulopathy, decreased
AAP, thrombocytopenia, and hemorrhage and/or thrombo-
sis) patients had advanced disease on presentation [5]. The
study identified forty-two PC patients with XFL and revealed
that most patients on presentation had metastatic disease
(95%), high-grade tumors (>50% with Gleason scores >7),
and castration-resistance disease (93%), received at least two
lines of therapy (90%), and received previous treatment with
taxanes (50%) [5]. Laboratory evaluation indicated elevated
D-dimers and PT, thrombocytopenia, lowAAP, and a normal
PTT range for the majority of patients. 79% of the patients
developed some bleeding complication that was intracuta-
neous (33%), genitourinary (26%), gastrointestinal (18%), and
intracranial (28%). The report indicated a median survival
of four weeks and reversal of DIC with XFL occurred in
only 18% of patients, all of whom received chemotherapy in
addition to supportive therapy with transfusions.This cohort
of patients had an improved median survival of 26 weeks in
comparison to patients who did not achieve a DIC and XFL
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Positive Positive fibrinmonomer test.
Positive fibrin monomer
and uPA tests.
AAP: alpha 2 antiplasmin; DIC: disseminated intravascular coagulation;
FDP: fibrin degradation product; INR: international normalized ratio; PAP:
plasmin-antiplasmin complex; PLTs: platelets; PT: prothrombin time; PTT:
partial thromboplastin time; TAT: thrombin-antithrombin complex; uPA:
urinary-type plasminogen activators; XFL: excessive fibrinolysis.
reversal, highlighting the importance of both prompt recog-
nition and treatment. Similar to the aforementioned survival
findings our patient had poor prognosis and succumbed to
his illness almost one year since diagnosis.
A case report of a 51-year-old male who presented with
extensive purpura and anemia was admitted to the hospital
and labs revealed elevated PT, PTT, thrombin-antithrombin
complex, fibrin degradation products (FDPs),D-dimers, plas-
min-antiplasmin complex (PAP), normal PLTs, positive fibrin
monomer test, and low AAP [8]. Immunohistochemical
stains of biopsied prostate cancer cells were positive for TF
and uPA confirming PC as the cause of DIC with XFL. Treat-
ment with low-molecular-weight heparin (LMWH) failed to
improve fibrinolytic markers by increasing fibrinogen, D-
dimers/FDP ratio, and AAP or decreasing PAP. Lack of imp-
rovement with anticoagulation suggested a stronger primary
fibrinolytic drive. With the addition of tranexamic acid, the
authors reported an increase in AAP and fibrinogen and
improvement in the remaining fibrinolytic markers corrob-
orating the premise of uncompensated XFL drive. Common
distinctive laboratory findings between DIC and XFL are
depicted in Table 1. Our patient’s laboratory work indicated
low fibrinogen and AAP and coagulopathy alluding to a state
of DIC with XFL. One of the limitations of our case report
is the lack of histological confirmation. A biopsy was not
attempted during hospitalization due to significant risk of
bleeding and during outpatient followup the patient declined
a biopsy in fear of recurrent bleeding. Another limitation
is that a repeat AAP and baseline fibrinogen-degradation
products were not obtained.
Many different therapies have been applied to patients
who develop PC with DIC and XFL. Cooper et al. reported
successfully using epsilon-aminocaproic and low-dose hep-
arin to treat a patient with DIC with XFL [12]. Leong et al.
attempted nuclearmedicine with Strontium-89 but it failed at
controlling bleeding and in fact worsened coagulopathy [13].
Review of the literature highlighted success with ketocona-
zole, a drug that can achieve castrate levels of testosterone
within 48 hours and does not cause an androgen surge seen
with GnRH analogues [14, 15]. Our patient was not treated
with ketoconazole due toQTprolongation on EKG. Initiation
of GnRH agonists alone in the treatment of PC with XFL
has been avoided due to concerns that an androgen surge
can deteriorate coagulopathy and lead to other complications,
such as cord compression in our patient due to the epidural
deposits [16].The benefit of combining ketoconazole to other
hormonal therapies to increase efficacy is unclear [17]. Other
hormonal treatment strategies attempted include estrogen
analogues; however, this is not recommended given the con-
cern of worsening coagulation and other reports implicating
worsening DIC and XFL in some cases [18–21]. Other suc-
cessful treatment strategies reported included treatment with
combined LMWH, tranexamic acid, and high dose antian-
drogen therapy [8]. Treatment with bicalutamide and leupro-
lide has also been successful [3]. The standard of care has
been treatment with chemotherapy reserved for patients not
responding to hormonal therapies or have castrate-resistant
disease. However, a recent trial enrolled 790 patients with
metastatic hormone-sensitive disease and randomized them
to androgen deprivation therapy (ADT) with or without doc-
etaxel (75mg/m2 every 3 weeks for 6 cycles) [22]. The results
of the trial revealed better cancer control, longer time to the
development of castration resistance, higher rate of decrease
of PSA level, lower number of prostate-cancer deaths, and
substantially longer overall survival in the combination
group. Maximum benefit with a median overall survival of
17 months was derived in patients with high-volume disease
defined as presence of visceral metastasis or four or more
bony lesions with at least one lesion beyond the vertebral
bodies or pelvis. Another trial highlighted a survival benefit
to the addition of docetaxel but not zoledronic acid to hor-
monal therapy in patients with high risk locally advanced or
metastatic prostate cancer [23]. Conversely, there are no data
on the effectiveness of either of those regimens in patients
with PC and XFL specifically.
A variety of cytotoxic therapies including mitoxantrone/
prednisone, docetaxel and cisplatin, and single agent doce-
taxel have been tried with some success in patients with PC
and XFL [5, 24, 25]. Degarelix is a third generation LHRH
antagonist used in men with prostate carcinoma and where
hormonal treatment is indicated [26]. This drug antagonizes
pituitary GnRH receptors thus suppressing gonadotropin
(LH and FSH) release leading to reduction in testicular
steroidogenesis. It was approved by the US Food and Drug
Administration in 2008 for androgen-dependent prostate
cancer [26]. Data from a Phase III clinical trial that led to
its approval demonstrated that degarelix achieved faster PSA
suppression and no testosterone surge compared to leupro-
lide [27]. The clinical trial revealed testosterone suppression
in a vast majority of patients after 3 days compared to leupro-
lide at 14 days. This advantageous medication profile was
particularly important for our patient since his tumor burden
was directly related to the extensive fibrinolysis and a delay
in response or an increase in testosterone would likely have
worsened his condition. To the best of our knowledge this
is the first reported case of successful treatment of DIC with
XFL with a single injection of degarelix.
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3. Conclusion
PCwithXFL is a distinctive hematological complication asso-
ciated with life-threatening bleeding, advanced disease at
presentation, high-grade and castrate-resistant disease, and
poor prognosis. Prompt diagnosis in patients presenting with
idiopathic coagulopathy and fibrinolysis is paramount and
early treatment is crucial to prevent mortality due to acute
severe bleeding. Supportive therapy with transfusions should
be started immediately and early PC directed therapy with
antiandrogens such as degarelix, ketoconazole, or chemother-
apy can be life saving for patients with PC and XFL.
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